- Home
- AVBH vs PROK Comparison
AVBH vs PROK Comparison
Compare AVBH & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVBH | PROK |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | 151 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.3M | 296.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AVBH | PROK |
|---|---|---|
| Price | $30.42 | $1.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $34.33 | $7.40 |
| AVG Volume (30 Days) | 56.0K | ★ 1.0M |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | $350.70 | N/A |
| Revenue Next Year | $11.40 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $22.95 | $0.54 |
| 52 Week High | $31.61 | $7.13 |
Technical Indicators
Market Signals| Indicator | AVBH | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 67.17 | 42.71 |
| Support Level | $29.23 | $1.71 |
| Resistance Level | $31.41 | $2.58 |
| Average True Range (ATR) | 0.64 | 0.12 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 67.90 | 2.82 |
Price Performance
Historical ComparisonAbout AVBH Avidbank Holdings Inc.
Avidbank Holdings Inc is a full-service commercial bank. It offers various services such as commercial and industrial lending, venture lending, structured finance, asset-based lending, sponsor finance, real estate construction, and commercial real estate lending.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.